PLoS One:血肌酐可预测血透患者死亡风险

2016-05-31 phylis 译 MedSci原创

背景:高体重指数(BMI)与血液透析(HD)患者疗效较好相关。本研究旨在探讨血清肌酐(Cr)这种肌肉质量的标记物,是否可以改变HD患者BMI与死亡率和发病率的关系。方法:日本的研究者从日本透析治疗登记的全国性的数据库中获得数据,进行回顾性的研究。共入选患者119099例(年龄:65±12岁,HD的中位数时间为5.6年,男性占62%),研究者探讨了1年后BMI与死亡率和发病率的相关性。按照BMI将患

背景:高体重指数(BMI)与血液透析(HD)患者疗效较好相关。本研究旨在探讨血清肌酐(Cr)这种肌肉质量的标记物,是否可以改变HD患者BMI与死亡率和发病率的关系。

方法:日本的研究者从日本透析治疗登记的全国性的数据库中获得数据,进行回顾性的研究。共入选患者119099例(年龄:65±12岁,HD的中位数时间为5.6年,男性占62%),研究者探讨了1年后BMI与死亡率和发病率的相关性。按照BMI将患者分为4组,或者按照血肌酐水平分成3组。应用多元回归分析法计算OR值和95%CI。

结果:高BMI不能预测1年总死亡率。然而,按照血肌酐将患者分层时,最低血肌酐水平的肥胖患者,心脏死亡的风险显著升高,男性OR值为2.82 [ 1.51-5.27 ],女性的OR值为2 [ 1.03-3.90 ]。最低的血肌酐水平肥胖男性患者,心脑梗死的风险较高。相反,高水平血肌酐的非肥胖患者,心脏、脑血管和感染相关的死亡水平显著降低。高血肌酐与非肥胖HD患者心血管事件风险降低相关。

结论:血液透析患者出现的肥胖的悖论,仅适用于用体重指数定义肥胖时。血肌酐水平较低与所有BMI患者不良预后相关。因此,无论患者体重指数如何,一旦接受常规血液透析,血肌酐水平均可用于预测死亡的发生。

原始出处:

Sakao Y, Ojima T, et al. Serum Creatinine Modifies Associations between Body Mass Index and Mortality and Morbidity in Prevalent Hemodialysis Patients. PLoS One. 2016 Mar 1.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789814, encodeId=986b1e89814c2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Aug 04 03:12:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983475, encodeId=d3cb19834e5f1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 20 19:12:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255564, encodeId=25d31255564bb, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293416, encodeId=5cab129341678, content=<a href='/topic/show?id=1d44810e5f7' target=_blank style='color:#2F92EE;'>#肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81075, encryptionId=1d44810e5f7, topicName=肌酐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428885, encodeId=d01414288857d, content=<a href='/topic/show?id=afdb89895bb' target=_blank style='color:#2F92EE;'>#血肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89895, encryptionId=afdb89895bb, topicName=血肌酐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79064143263, createdName=ying_wu, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466429, encodeId=2a911466429b5, content=<a href='/topic/show?id=1a808996802' target=_blank style='color:#2F92EE;'>#血透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89968, encryptionId=1a808996802, topicName=血透)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=950a6811421, createdName=luwei02, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789814, encodeId=986b1e89814c2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Aug 04 03:12:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983475, encodeId=d3cb19834e5f1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 20 19:12:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255564, encodeId=25d31255564bb, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293416, encodeId=5cab129341678, content=<a href='/topic/show?id=1d44810e5f7' target=_blank style='color:#2F92EE;'>#肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81075, encryptionId=1d44810e5f7, topicName=肌酐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428885, encodeId=d01414288857d, content=<a href='/topic/show?id=afdb89895bb' target=_blank style='color:#2F92EE;'>#血肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89895, encryptionId=afdb89895bb, topicName=血肌酐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79064143263, createdName=ying_wu, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466429, encodeId=2a911466429b5, content=<a href='/topic/show?id=1a808996802' target=_blank style='color:#2F92EE;'>#血透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89968, encryptionId=1a808996802, topicName=血透)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=950a6811421, createdName=luwei02, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789814, encodeId=986b1e89814c2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Aug 04 03:12:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983475, encodeId=d3cb19834e5f1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 20 19:12:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255564, encodeId=25d31255564bb, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293416, encodeId=5cab129341678, content=<a href='/topic/show?id=1d44810e5f7' target=_blank style='color:#2F92EE;'>#肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81075, encryptionId=1d44810e5f7, topicName=肌酐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428885, encodeId=d01414288857d, content=<a href='/topic/show?id=afdb89895bb' target=_blank style='color:#2F92EE;'>#血肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89895, encryptionId=afdb89895bb, topicName=血肌酐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79064143263, createdName=ying_wu, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466429, encodeId=2a911466429b5, content=<a href='/topic/show?id=1a808996802' target=_blank style='color:#2F92EE;'>#血透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89968, encryptionId=1a808996802, topicName=血透)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=950a6811421, createdName=luwei02, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1789814, encodeId=986b1e89814c2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Aug 04 03:12:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983475, encodeId=d3cb19834e5f1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 20 19:12:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255564, encodeId=25d31255564bb, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293416, encodeId=5cab129341678, content=<a href='/topic/show?id=1d44810e5f7' target=_blank style='color:#2F92EE;'>#肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81075, encryptionId=1d44810e5f7, topicName=肌酐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428885, encodeId=d01414288857d, content=<a href='/topic/show?id=afdb89895bb' target=_blank style='color:#2F92EE;'>#血肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89895, encryptionId=afdb89895bb, topicName=血肌酐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79064143263, createdName=ying_wu, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466429, encodeId=2a911466429b5, content=<a href='/topic/show?id=1a808996802' target=_blank style='color:#2F92EE;'>#血透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89968, encryptionId=1a808996802, topicName=血透)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=950a6811421, createdName=luwei02, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-06-02 俅侠
  5. [GetPortalCommentsPageByObjectIdResponse(id=1789814, encodeId=986b1e89814c2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Aug 04 03:12:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983475, encodeId=d3cb19834e5f1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 20 19:12:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255564, encodeId=25d31255564bb, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293416, encodeId=5cab129341678, content=<a href='/topic/show?id=1d44810e5f7' target=_blank style='color:#2F92EE;'>#肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81075, encryptionId=1d44810e5f7, topicName=肌酐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428885, encodeId=d01414288857d, content=<a href='/topic/show?id=afdb89895bb' target=_blank style='color:#2F92EE;'>#血肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89895, encryptionId=afdb89895bb, topicName=血肌酐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79064143263, createdName=ying_wu, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466429, encodeId=2a911466429b5, content=<a href='/topic/show?id=1a808996802' target=_blank style='color:#2F92EE;'>#血透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89968, encryptionId=1a808996802, topicName=血透)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=950a6811421, createdName=luwei02, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-06-02 ying_wu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1789814, encodeId=986b1e89814c2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Aug 04 03:12:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983475, encodeId=d3cb19834e5f1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 20 19:12:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255564, encodeId=25d31255564bb, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293416, encodeId=5cab129341678, content=<a href='/topic/show?id=1d44810e5f7' target=_blank style='color:#2F92EE;'>#肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81075, encryptionId=1d44810e5f7, topicName=肌酐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428885, encodeId=d01414288857d, content=<a href='/topic/show?id=afdb89895bb' target=_blank style='color:#2F92EE;'>#血肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89895, encryptionId=afdb89895bb, topicName=血肌酐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79064143263, createdName=ying_wu, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466429, encodeId=2a911466429b5, content=<a href='/topic/show?id=1a808996802' target=_blank style='color:#2F92EE;'>#血透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89968, encryptionId=1a808996802, topicName=血透)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=950a6811421, createdName=luwei02, createdTime=Thu Jun 02 06:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-06-02 luwei02

相关资讯

J Occup Environ Med:驾驶员体重指数和肥胖及并发症之间的关系

目的:本研究的目的是评估体重指数(BMI)和多数卡车司机肥胖并发症情况之间的关系。 方法: 抽查了2005到2012年之间88246名职业司机的体检资料进行分析,分析其体重指数、肥胖疾病和司机执照之间的关系。 结果:大多数司机都是肥胖的(53.3%,BMI大于30.0 kg/m),病态肥胖的(26.6%,BMI大于35.0 kg/m),高于先前的报道。肥胖的司机2年不太可能注册的,更容易出现心

Environ Res:交通噪声污染可引起肥胖

Environ Res:交通噪声污染可引起肥胖                近日来自挪威公共卫生学院的一项研究表明,交通噪声可能会引起肥胖。该研究成果于2015年4月在线发表于Environ Res。既往有研究表明噪声与内分泌变化和心血管疾病有关。噪声引起的

AHJ:警惕!男性空腹血糖受损可能是静息性心梗的征兆

AHJ:警惕!空腹血糖受损可能是静息性心梗的征兆据发表于 American Heart Journal的一项新的研究表明,空腹血糖受损(IFG)可能是成人静息性心梗的一个预测因子。来自MESA的一项研究表明,在近6000名参与者中,与空腹血糖正常者相比,IFG患者发生静息性心梗的可能性更高(校正后[OR ] 1.60,95% CI 1.0-2.5)。男性其IFG与静息性心梗的发生存在显著的相关性(

LANCET:肥胖增加患癌风险

LANCET:肥胖增加患癌风险 研究背景:虽然以往研究证实高体重指数(BMI)增加多种患癌风险,但是以往研究并没有考虑到影响BMI的混杂因素,以及样本例数不够,BMI测量偏倚等,因此有其局限性。 研究目的:更准确的评价BMI与各种癌症的关系。 研究方法:从英国临床实践研究数据库(CPRD)中调取1987-2012年的所有大于16岁的524万名患者信息,结局指标为22种恶性肿瘤。 研究结

Int J Cardiol:房颤患者白质高信号与认知功能损害不相关

背景:本研究旨在心房颤动(AF)脑颅脑磁共振成像(MRI)显示白质高信号(WMH)的发生,严重程度及危险因素,并且确定WMH和认知功能下降之间的关系。方法:招募阵发性非瓣膜性房颤患者74名,年龄59(IQR 50-63)岁,男性45 / 61%。纳入前,所有的患者给予充分的华法林治疗,并且这些患者无卒中或TIA病史。根据法泽卡斯量表将脑WMH存在及严重程度进行分类,应用简易精神状态检查(MMSE)

J Periodonto:超重和肥胖可增加牙周炎发病的风险

J Periodonto:超重和肥胖可增加牙周炎发病的风险关键词:肥胖 体重指数 牙周炎 口腔健康 炎症超重和肥胖被定义为脂肪堆积过多,可能会损害健康。如果成人的体重指数(BMI=体重kg/身高2m)≥25,则被称为超重,如果BMI≥则30kg/m2 被认为是肥胖。在过去的几十年里,超重和肥胖的患病率一直在升高,对健康和社会经济造成了影响,故引起了社会的广泛关注。肥胖会伴随着一种低炎症状态,现已发